Scholars Central

Conference abstractPublished 13 Oct 2016

Structural insight into mechanisms of inactivation of L, D transpeptidases by carbapenems

Authors: Mario Antonio Bianchet

Johns Hopkins School of Medicine, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Carbapenems are among the most potent antimicrobial Ã?²-lactams available today. Emerging evidence indicates that, unlike other subclasses of Ã?²-lactams, carbapenems inhibit non-classical transpeptidases (L, D-transpeptidases) that generate 3âÂ?Â?3 linkages in the bacterial peptidoglycan. Five different L, D-transpeptidases form part of the cell-wall biosynthesis machinery in Mycobacterium tuberculosis (Mtb), being LdtMt2 the most consequential for mycobacteria survival. Homologous enzymes have been found in ESKAPE pathogens. Evidences show that the peptidoglycan structure produced by these enzymes confers antibiotic-resistant to strains of Enterococcus Faecium and Clostridium difficile. Biapenem, tebipenem and panipenem exhibit therapeutically valuable potencies against drug resistant pathogens. These three different carbapenems inactivate these enzymes by forming adducts with their catalytic cysteine and two other carbapenems, imipenem and meropenem docks to one of the two (inner and outer) cavities that access the catalytic site. The complexes of biapenem, tebipenem and panipenem with LdtMt2 provide evidence that the dock to the outer cavity as a preferred binding mode. Unexpectedly, biapenem and tebipenem result in the same adduct resulted by an enzyme-catalyzed decomposition of the carbapenem resembling the S-conjugate elimination by Ã?² lyases. This elimination could be used to our advantage to the targeted delivery and release of the additional antimicrobial compounds. The binding mode and adduct stability are important factors to be considered in any antibiotic design based on the carbapenem scaffold. The potential correlations between these factors and carbapenems affectivity as antibiotics will be reviewed under the light of the structures of complexes of these carbapenems with LdtMt2.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Drug Metabolism & Toxicology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Drug Metabolism & Toxicology
  • SubjectDiabetes & Endocrinology
  • SubjectPharmaceutical Sciences
  • SubjectToxicology
  • BylineArticles whose byline prints “Mario Antonio Bianchet”